Zheng Qi, Liu Bangshan, Xu Shuyin, Liao Mei, Zhang Yan, Li Lingjiang
Mental Health Institute, Second Xiangya Hospital, Central South University; National Clinical Research Center for Mental Disorder; National Technology Institute of Psychiatry; Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha 410011, China.
Department of Human Anatomy and Neuroscience, School of Basic Medicine, Central South University, Changsha 410013, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Apr 28;42(4):476-480. doi: 10.11817/j.issn.1672-7347.2017.04.018.
Cognition deficit is one of the most common symptoms of schizophrenia, including abstract thinking and memory, and attention deficits. Previous studies have suggested that the improvement of cognition is very important for the recovery of disease and social function for the patients. Recent studies indicated that two new atypical antipsychotics, blonanserin and lurasidone, are expected to improve the cognitive impairment in patients with schizophrenia. This review introduces pathogenesis of cognitive impairment in schizophrenia, mechanisms of blonanserin and lurasidone in the improvement of cognitive impairment and progress in their clinical application for schizophrenia. We hope that this review could guide clinical use of antipsychotics and provide new directions for future studies.
认知缺陷是精神分裂症最常见的症状之一，包括抽象思维、记忆和注意力缺陷。以往研究表明，认知功能的改善对患者疾病康复和社会功能恢复非常重要。近期研究表明，两种新型非典型抗精神病药物，布南色林和鲁拉西酮，有望改善精神分裂症患者的认知障碍。本文综述了精神分裂症认知障碍的发病机制、布南色林和鲁拉西酮改善认知障碍的机制及其在精神分裂症临床应用中的进展。希望本文能指导抗精神病药物的临床应用，并为未来研究提供新方向。
